Please login to the form below

Not currently logged in
Email:
Password:

immune disease

This page shows the latest immune disease news and features for those working in and with pharma, biotech and healthcare.

Is acquisitive Celgene now eyeing CAR-T specialist Juno?

Is acquisitive Celgene now eyeing CAR-T specialist Juno?

The two companies are already partners, signing a 10-year collaboration in 2015 to co-develop drugs for cancer and immune disease. ... Celgene has been hit of late by downgraded sales estimates for its blood cancer drugs, as well as a failed clinical

Latest news

  • NICE backs GSK’s €594k gene therapy for rare disease NICE backs GSK’s €594k gene therapy for rare disease

    NICE backs GSK’ s 594k gene therapy for rare disease. The treatment offers 'bubble baby' patients an alternative to a stem cell transplant. ... Children with the rare disease have compromised immune systems and are extremely vulnerable to infections,

  • Spark’s Luxturna becomes US’s first approved gene therapy Spark’s Luxturna becomes US’s first approved gene therapy

    a policy framework - including the development of disease-specific guidance - “for the evaluation and review of gene therapy.”. ... GlaxoSmithKline took a more conservative approach with its Strimvelis gene therapy for immune-deficiency disease

  • NICE backs Pfizer’s Xeljanz for RA NICE backs Pfizer’s Xeljanz for RA

    Given in combination with methotrexate, the twice-daily administered drug is recommended for adults whose disease hasn’t responded adequately to intensive therapy with conventional or other disease-modifying anti-rheumatic ... According to the National

  • Sanofi and Ablynx sign €2.4bn nanobody deal Sanofi and Ablynx sign €2.4bn nanobody deal

    Sanofi and Ablynx sign 2.4bn nanobody deal. The duo will develop immune-mediated inflammatory disease candidates. ... The partners will focus on developing and commercialising nanobody-based therapeutics for the treatment of various immune-mediated

  • UniQure pulls first EU gene therapy UniQure pulls first EU gene therapy

    UniQure said there was simply not enough demand for Glybera (alipogene tiparvovec) - a treatment for patients with the ultra-rare inherited disease lipoprotein lipase deficiency (LPLD) - to warrant keeping it on ... GlaxoSmithKline (GSK), which was the

More from news
Approximately 1 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • Pharma deals in July 2015 Pharma deals in July 2015

    cCAM is developing an immune checkpoint protein belonging to the Human CEA (Carcino-Embryonic Antigen) protein family. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    658. Avalanche / Regeneron. Development and commercialisation licence. Gene therapy products for ophthalmologic disease. ... MGD010, a preclinical bispecific antibody for treatment of auto-immune disease. 502.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    Immuno-oncology. One area of interest for many pharma companies is the potential for immunotherapies - drugs that encourage the body's immune system to tackle a disease. ... or with other agents that might affect a different part of the immune system, or

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics